You are here
Zogenix Provides Corporate Update and Reports First Quarter Financial Results
- Following receipt of Breakthrough Therapy Designation, conducted successful Type B meeting with FDA confirming adequacy of Phase 3 program for ZX008 NDA in Dravet syndrome
- Study 1504 fully enrolled with 87 randomized patients; top-line results expected late June/early July
- On-track to submit U.S. and EU regulatory approval filings for ZX008 in Dravet syndrome in fourth quarter of 2018
EMERYVILLE, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the first quarter ended March 31, 2018.
“We continue to advance towards multiple key catalysts in our late-stage lead program, ZX008 for the treatment of Dravet syndrome, including results from our second Phase 3 trial, Study 1504, and U.S. and EU regulatory filings targeted for the fourth quarter of 2018,” said Stephen J. Farr, Ph.D., President and CEO of Zogenix. “To this end, following receipt of Breakthrough Therapy designation in the first quarter, we recently conducted a successful Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss our ZX008 clinical development program and planned New Drug Application (NDA) content for ZX008 in Dravet syndrome.”
“In addition, we continued to add to the positive efficacy data set for ZX008 in Dravet syndrome through the presentation of further analyses of Study 1, our first Phase 3 trial, in two poster presentations at the 2018 American Academy of Neurology (AAN) Annual Meeting,” continued Dr. Farr. “Importantly, the results of a post-hoc analysis evaluating the effect of ZX008 in a subset of patients who had previously failed treatment with stiripentol, a commonly used antiepileptic drug, showed that the efficacy and tolerability results in this subgroup were robust and comparable to those achieved in the full Study 1 population.”
“We also continued to enroll patients in our ongoing global Phase 3 trial of ZX008 in Lennox-Gastaut syndrome (LGS) in children and adults up to age 35, and had 16 open sites in the U.S. and Canada at the end of April and are focused on opening others in North America and completing Ethics Committee submissions to several European countries,” concluded Dr. Farr.
- Conducted a successful Breakthrough Therapy Type B meeting with the FDA regarding the ZX008 clinical development program and planned NDA submission in Dravet syndrome. Key outcomes included:
- Reaffirmation of Study 1 and Study 1504 as the clinical basis for the NDA submission;
- Concurrence that the anticipated ZX008 exposures in the Dravet syndrome program at the time of the NDA submission are likely to be sufficient to support the filing; and
- Agreement on the schedule for a rolling NDA submission.
- Enrolled and randomized a total of 87 patients into the efficacy cohort of Study 1504, with last patient scheduled to exit the treatment period at the end of May and top-line results expected end of June/early July.
- Presented new efficacy and safety results from Study 1 at the AAN 2018 Annual Meeting:
- Positive results of a post-hoc analysis evaluating the effect of ZX008 on controlling convulsive seizures in patients in Study 1 who had previously failed therapy with stiripentol. The data demonstrated that patients taking ZX008 0.8 mg/kg/day (max. 30 mg/day) achieved a 60.8% greater reduction in mean monthly convulsive seizures compared to placebo (p=0.002). Additionally, in the 0.8 mg/kg/day group, 72.7% of patients achieved an equal or greater than 50% reduction in convulsive seizures (p=0.006), and 50.0% achieved an equal or greater than 75% reduction (p=0.036). Across these and other efficacy measures, the results from the subset analysis of stiripentol non-responders were comparable to the full Study 1 population, indicating that a history of non-responsiveness to stiripentol is not a predictor of negative response to treatment with ZX008 in Dravet syndrome.
- Positive results of a prespecified secondary analysis evaluating the effect of ZX008 on total seizure frequency, showing that treatment with ZX008 at doses of 0.2 mg/kg/day and 0.8 mg/kg/day (max. 30 mg/day) resulted in significantly greater reductions in median monthly total seizure frequency compared to placebo (p= 0.031 and p<0.001, respectively).
- Encouraging preliminary quality of life and cognitive function data showing that patients treated with ZX008 over the 14-week double-blind treatment period experienced significant improvements on select measures of quality of life and executive function compared to those on placebo.
- Continued enrollment in global Phase 3 trial of ZX008 for treatment of LGS, Study 1601. At the end of April, 16 sites in the U.S. and Canada were open to recruit patients and Ethics Committee submissions to several European countries have been completed.
First Quarter 2018 Financial Results
- Due to the wind-down of Sumavel DosePro manufacturing operations in September 2017, the Company recorded no revenue for the three months ended March 31, 2018. This compares with total revenue of $2.7 million in the first quarter ended March 31, 2017, consisting entirely of contract manufacturing revenue for Sumavel DosePro.
- Research and development expenses for the first quarter ended Mach 31, 2018, totaled $23.0 million, up from $13.3 million in the first quarter ended March 31, 2017, as the Company continued enrollment and expanded the scope of its Phase 3 clinical trials for ZX008 in Dravet syndrome and LGS.
- Selling, general and administrative expenses for the first quarter ended March 31, 2018, totaled $8.1 million, compared with $6.6 million in the first quarter ended March 31, 2017.
- Net loss from continuing operations for the first quarter ended March 31, 2018, was $30.2 million, compared with a net loss from continuing operations of $21.1 million in the first quarter ended March 31, 2017.
- Total net loss for the first quarter ended March 31, 2018, was $30.2 million, or a net loss of $0.87 per share, compared with a total net loss of $21.3 million, or a net loss of $0.86 per share, in the first quarter ended March 31, 2017.
- As of March 31, 2018, the Company had cash and cash equivalents of $272.0 million, compared to $293.5 million at December 31, 2017.
Conference Call Details
|Wednesday, May 9th @ 4:30pm Eastern Time/1:30pm Pacific Time|
|Replays, available through May 23rd|
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com
Forward Looking Statements
Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests,” “assuming,” “designed” and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding ZX008’s potential as a treatment for seizures associated with Dravet syndrome; the enrollment of patients in the planned global Phase 3 clinical trial in Lennox Gastaut Syndrome; the timing of top line results for the Study 1504 clinical trial; the timing or results of regulatory submissions for ZX008 for Dravet syndrome in the U.S. and Europe; the timing of the enrollment of patients or results in our Phase 3 trial in LGS; the timing of our regulatory submissions of ZX008 to treat LGS; and the commercial potential of ZX008. The inclusion of forward-looking statements should not be regarded as a representation by Zogenix that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in Zogenix’s business, including, without limitation: the uncertainties associated with the clinical development and regulatory approval of product candidates such as ZX008, including potential delays in the commencement, enrollment and completion of clinical trials; the potential that earlier clinical trials and studies, and analyses of such clinical trials and studies, may not be predictive of future results; top-line data is based on preliminary analysis of clinical data, and such data may change following a more comprehensive review of the data related and such top-line data may not accurately reflect the complete results of a clinical trial; Zogenix’s reliance on third parties to conduct its clinical trials, enroll patients, manufacture its preclinical and clinical drug supplies and manufacture commercial supplies of its drug products, if approved; unexpected adverse side effects or inadequate therapeutic efficacy of ZX008 that could limit approval and/or commercialization, or that could result in recalls or product liability claims; Zogenix's ability to fully comply with numerous federal, state and local laws and regulatory requirements, as well as rules and regulations outside the United States, that apply to its product development activities; Breakthrough Therapy designation and Fast Track designation may not result in an expedited regulatory review process; and other risks described in Zogenix’s prior press releases as well as in public periodic filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except par value)
|Cash and cash equivalents||$||271,953||$||293,503|
|Other current assets||827||5,206|
|Total current assets||281,327||304,703|
|Property and equipment, net||287||245|
|Liabilities and stockholders’ equity|
|Common stock warrant liabilities||495||512|
|Total current liabilities||23,076||20,983|
|Deferred income taxes||17,425||17,425|
|Other long-term liabilities||684||784|
|Additional paid-in capital||875,957||873,526|
|Total stockholders’ equity||273,772||301,521|
|Total liabilities and stockholders’ equity||$||391,857||$||417,613|
Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except per share amounts)
|Three Months Ended March 31,|
|Contract manufacturing revenue||$||—||$||2,696|
|Costs and expenses:|
|Cost of contract manufacturing||—||2,487|
|Research and development||22,980||13,341|
|Selling, general and administrative||8,070||6,554|
|Asset impairment charges||—||813|
|Change in fair value of contingent consideration||—||600|
|Total costs and expenses||31,050||23,795|
|Loss from operations||(31,050||)||(21,099||)|
|Other income (expense):|
|Change in fair value of common stock warrant liabilities||17||587|
|Other income (expense)||26||(20||)|
|Total other income (expense)||870||(10||)|
|Loss from continuing operations before income taxes||(30,180||)||(21,109||)|
|Income tax expense||—||(17||)|
|Net loss from continuing operations||(30,180||)||(21,126||)|
|Loss from discontinued operations, net of tax||—||(181||)|
|Net loss per share, basic and diluted:|
|Weighted-average shares used in computing net loss per share, basic and diluted||34,841||24,813|